How to Cite
Abstract
The classic oral anticoagulants were exclusively used for more than 65 years, the effectiveness they have to treat thromboembolic events and their complications is known, in addition to this they have other advantages, such as low economic cost and the availability of antidotes, However, they have a wide variety of limitations and side effects, due to this and the prevalence of thromboembolic diseases in the growing geriatric population, new oral anticoagulants (NACOs) are developed, created to reinforce the limitations and reduce the adverse effects of classic anticoagulants, these drugs reached their peak with the approval of antidotes such as idarucizumab a monoclonal antibody that inhibits dabigatran and andexanet alfa a drug with the potential to reverse the effects of direct and indirect factor Xa inhibitors.
Keywords
References
Grand B. Historia del descubrimiento de los agentes antitrombóticos clásicos: aspirina, heparina y anticoagulantes orales. Una serendipia con perseverancia. SAH [Internet]. 2018 [citado 16 Dic 2019]; 22 (1): 95-102. Disponible en: http://www.sah.org.ar/revista/numeros/vol22/n1/15-vol22-n1.pdf
Pereyra R.C. La Heparina el antitrombótico universal cumple un siglo salvando vidas humanas. Rev. Soc. Peruana Med. Interna [Internet]. 2016 [citado 24 Ene 2020]; 29(3): 86-88. Disponible en: http://medicinainterna.net.pe/images/REVISTAS/2016/revista_03/editorial.pdf
Singh D. 100 Years of Heparin (1916-2016): Saga of Joys and Tears. Indian Journal of Vascular and Endovascular Surgery. 2016;3(4):128. https://doi.org/10.4103/0972-0820.191492
Harenberg J. Past, present, and future perspectives of heparins in clinical settings and the role of impaired renal function. International Journal of Cardiology. 2016 06;212:S10-S13. https://doi.org/10.1016/s0167-5273(16)12003-0
Hemker HC. A century of heparin: past, present and future. Journal of Thrombosis and Haemostasis. 2016 Dec;14(12):2329-2338. https://doi.org/10.1111/jth.13555
Van Gorp R, Schurgers L. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients. 2015 Nov 17;7(11):9538-9557. https://doi.org/10.3390/nu7115479
Shehab A, Elnour AA, Bhagavathula AS, Erkekoglu P, Hamad F, Al Nuaimi S, Al Shamsi A, Mukhtar I, Ali AbdElrazek AM, Al Suwaidi A, Mandil MA, Baraka M, Sadik A, Saraan K, Al Kalbani NM, Mahmood AA, Barqawi Y, Al Hajjar M, Shehab OA, Al Amoodi A, Asim S, Abdulla R, Giraud CS, Ahmed EM, Shaaban ZA, Eltayeb AEYA. Novel oral anticoagulants and the 73rd anniversary of historical warfarin. Journal of the Saudi Heart Association. 2016 01;28(1):31-45. https://doi.org/10.1016/j.jsha.2015.05.003
Ramachandran S, Pitchai S. Story of warfarin: From rat poison to lifesaving drug. Indian Journal of Vascular and Endovascular Surgery. 2018;5(3):174. https://doi.org/10.4103/ijves.ijves_49_18
Hunt BJ, Levi M. Engineering Reversal — Finding an Antidote for Direct Oral Anticoagulants. New England Journal of Medicine. 2016 09 22;375(12):1185-1186. https://doi.org/10.1056/nejme1610510
Berkovits A, Mezzano D. Nuevos anticoagulantes orales: actualización. Revista chilena de cardiología. 2017 Dec;36(3):254-263. https://doi.org/10.4067/s0718-85602017000300254
Goldhaber Samuel Z. Trombosis venosa profunda y tromboembolia pulmonar. En: Jameson JL, Kasper DL, Longo DL, et al, editores. Harrison principios de medicina interna. Vol2. 20va ed. México: McGraw-Hill; 2018. p. 1910-1916.
Bauer KA. Targeted Anti-Anticoagulants. N Engl J Med [Internet]. 2015 [citado 19 Dic 2019];373:569-571. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMe1506600
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disvantages compared with vitamin K antagonist in the prevention treatment of patients with thromboembolic events. Ther Clin Risk Manag [Internet]. 2015 [citado 24 Ene 2020];11:967-977. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485791/
Goldhaber SZ. Embolia Pulmonar. En: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editores. Braunwald tratado de cardiología. Vol 2. 10a ed. España: Elsevier; 2016. p.1664-1679.
Barbieri RL, Repke JT. Trastornos médicos durante el embarazo. En: Jameson JL, Kasper DL, Longo DL, et al, editores. Harrison principios de medicina interna. Vol2. 20va ed. México: McGraw-Hill; 2018. p. 3440-3446.
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). EHJ. 2019;0(0):1-61
https://doi.org/10.1093/eurheartj/ehz405
Mega JL, Morrow DA. Infarto de miocardio con elevación del ST: tratamiento. En: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editores. Braunwald tratado de cardiología. Vol 2. 10a ed. España: Elsevier; 2016. p.1095-1154
Antman EM, Loscalzo J. Infarto de miocardio con elevación del segmento ST. En: Jameson JL, Kasper DL, Longo DL, et al, editores. Harrison principios de medicina interna. Vol2. 20va ed. México: McGraw-Hill; 2018. p. 1872-1885.
Borja I, Stefan J, Stefan A, Antunes M, Bucciarelli-Ducci C, Bueno H et al. Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Rev Esp Cardiol [Internet]. 2017 [citado 16 Oct 2019];70(12): 1082.e1-e61. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893217306693
Barrabés J. Comentarios a la guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología. 2015 Dec;68(12):1061-1067. https://doi.org/10.1016/j.recesp.2015.11.001
Corrección en el artículo de Kirchhof et al. «Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS». Rev Esp Cardiol. 2017;70:50.e1-e84. Revista Española de Cardiología. 2017 Nov;70(11):1031. https://doi.org/10.1016/j.recesp.2017.07.028
Morady F, Zipes DP. Fibrilación auricular: clínicas, mecanismos y tratamiento. En: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editores. Braunwald tratado de cardiología. Vol 1. 10a ed. España: Elsevier; 2016. p.798-820.
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine. 2016 Dec 22;375(25):2423-2434. https://doi.org/10.1056/nejmoa1611594
Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam C, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. New England Journal of Medicine. 2017 08 03;377(5):431-441. https://doi.org/10.1056/nejmoa1707278
Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2016 09 22;375(12):1131-1141. https://doi.org/10.1056/nejmoa1607887